Pauline Verdijk1, Nynke Y Rots2, Monique G C T van Oijen3, William C Weldon4, M Steven Oberste5, Hiromasa Okayasu6, Roland W Sutter7, Wilfried A M Bakker8. 1. Institute for Translational Vaccinology (Intravacc), P.O. Box 450, 3720 AL Bilthoven, The Netherlands. Electronic address: pauline.verdijk@intravacc.nl. 2. Centre for Infectious Diseases Control, National Institute for Public Health and the Environment (RIVM), P.O. Box 1, 3720 BA Bilthoven, The Netherlands. Electronic address: Nynke.rots@rivm.nl. 3. Institute for Translational Vaccinology (Intravacc), P.O. Box 450, 3720 AL Bilthoven, The Netherlands. Electronic address: Monique.van.oijen@intravacc.nl. 4. Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30333, USA. Electronic address: Wiw4@cdc.gov. 5. Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30333, USA. Electronic address: Mbo2@cdc.gov. 6. World Health Organization, Avenue Appia 20, 1211 Geneva 27, Switzerland. Electronic address: okayasuhi@who.int. 7. World Health Organization, Avenue Appia 20, 1211 Geneva 27, Switzerland. Electronic address: sutterr@who.int. 8. Institute for Translational Vaccinology (Intravacc), P.O. Box 450, 3720 AL Bilthoven, The Netherlands. Electronic address: Wilfried.bakker@intravacc.nl.
Abstract
BACKGROUND: An inactivated poliovirus vaccine (IPV) based on attenuated poliovirus strains (Sabin-1, -2 and -3) was developed for technology transfer to manufacturers in low- and middle-income countries in the context of the global polio eradication initiative. METHOD: Safety and immunogenicity of Sabin-IPV (sIPV) was evaluated in a double-blind, randomized, controlled, dose-escalation trial in the target population. Healthy infants (n=20/group) aged 56-63 days, received a primary series of three intramuscular injections with low-, middle- or high-dose sIPV with or without aluminum hydroxide or with the conventional IPV based on wild poliovirus strains (wIPV). Virus-neutralizing titers against both Sabin and wild poliovirus strains were determined before and 28 days after three vaccinations. RESULTS: The incidence of local and systemic reactions was comparable with the wIPV. Seroconversion rates after three vaccinations were 100% for type 2 and type 3 polioviruses (both Sabin and wild strains) and 95-100% for type 1 polioviruses. Median titers were high in all groups. Titers were well above the log2(titer) correlated with protection (=3) for all groups. Median titers for Sabin-2 were 9.3 (range 6.8-11.5) in the low-dose sIPV group, 9.2 (range 6.8-10.2) in the low-dose adjuvanted sIPV group and 9.8 (range 5.5-15.0) in the wIPV group, Median titers against MEF-1 (wild poliovirus type 2) were 8.2 (range 4.8-10.8) in the low-dose sIPV group, 7.3 (range 4.5-10.2) in the low-dose adjuvanted Sabin-IPV group and 10.3 (range 8.5-17.0) in the wIPV group. For all poliovirus types the median titers increased with increasing dose levels. CONCLUSION: sIPV and sIPV adjuvanted with aluminum hydroxide were immunogenic and safe at all dose levels, and comparable with the wIPV. EudraCTnr: 2011-003792-11, NCT01709071.
BACKGROUND: An inactivated poliovirus vaccine (IPV) based on attenuated poliovirus strains (Sabin-1, -2 and -3) was developed for technology transfer to manufacturers in low- and middle-income countries in the context of the global polio eradication initiative. METHOD: Safety and immunogenicity of Sabin-IPV (sIPV) was evaluated in a double-blind, randomized, controlled, dose-escalation trial in the target population. Healthy infants (n=20/group) aged 56-63 days, received a primary series of three intramuscular injections with low-, middle- or high-dose sIPV with or without aluminum hydroxide or with the conventional IPV based on wild poliovirus strains (wIPV). Virus-neutralizing titers against both Sabin and wild poliovirus strains were determined before and 28 days after three vaccinations. RESULTS: The incidence of local and systemic reactions was comparable with the wIPV. Seroconversion rates after three vaccinations were 100% for type 2 and type 3 polioviruses (both Sabin and wild strains) and 95-100% for type 1 polioviruses. Median titers were high in all groups. Titers were well above the log2(titer) correlated with protection (=3) for all groups. Median titers for Sabin-2 were 9.3 (range 6.8-11.5) in the low-dose sIPV group, 9.2 (range 6.8-10.2) in the low-dose adjuvanted sIPV group and 9.8 (range 5.5-15.0) in the wIPV group, Median titers against MEF-1 (wild poliovirus type 2) were 8.2 (range 4.8-10.8) in the low-dose sIPV group, 7.3 (range 4.5-10.2) in the low-dose adjuvanted Sabin-IPV group and 10.3 (range 8.5-17.0) in the wIPV group. For all poliovirus types the median titers increased with increasing dose levels. CONCLUSION: sIPV and sIPV adjuvanted with aluminum hydroxide were immunogenic and safe at all dose levels, and comparable with the wIPV. EudraCTnr: 2011-003792-11, NCT01709071.
Authors: Hui-Ting Chan; Yuhong Xiao; William C Weldon; Steven M Oberste; Konstantin Chumakov; Henry Daniell Journal: Plant Biotechnol J Date: 2016-06-01 Impact factor: 9.803
Authors: Edward Pk Parker; Natalie A Molodecky; Margarita Pons-Salort; Kathleen M O'Reilly; Nicholas C Grassly Journal: Expert Rev Vaccines Date: 2015-07-09 Impact factor: 5.217
Authors: Barbara P Sanders; Isabel de Los Rios Oakes; Vladimir van Hoek; Viki Bockstal; Tobias Kamphuis; Taco G Uil; Yutong Song; Gillian Cooper; Laura E Crawt; Javier Martín; Roland Zahn; John Lewis; Eckard Wimmer; Jerome H H V Custers; Hanneke Schuitemaker; Jeronimo Cello; Diana Edo-Matas Journal: PLoS Pathog Date: 2016-03-31 Impact factor: 6.823
Authors: Ananda S Bandyopadhyay; Edwin J Asturias; Miguel O'Ryan; M Steven Oberste; William Weldon; Ralf Clemens; Ricardo Rüttimann; John F Modlin; Chris Gast Journal: Vaccine Date: 2017-11-14 Impact factor: 3.641